**Simple answer: A complete cure for herpes (HSV-1 and HSV-2) is still not available in 2026.** The position of authoritative bodies such as the World Health Organization and the NIH is clear: existing antiviral drugs can only inhibit the active replication of the virus, but cannot completely clear the dormant (latent) virus in neurons. However, a truly significant advancement has been made in 2026—**Pritelivir (Hovilpri) has been approved by the FDA**, which is the first new-action herpes treatment drug in nearly 30 years, but it is only for specific patient groups and is not a cure.
 |
|
## Most Important Advancement of 2026: Pritelivir Approved
On October 9, 2026, the US FDA approved Pritelivir (brand name Hovilpri) tablets for the treatment of adult patients with weakened immune systems (such as those with organ transplants, HIV infection, blood cancers), whose mucocutaneous HSV infection is resistant to or has not sufficiently responded to conventional medications (acyclovir, valacyclovir, famciclovir).
This drug belongs to the helicase-primase inhibitor class, which works in a completely different way from conventional medications. Conventional drugs require activation by the virus's thymidine kinase (TK), and mutations in TK are the main cause of drug resistance. Pritelivir acts directly on the virus's DNA replication mechanism, so it is also sensitive to TK-deficient, acyclovir-resistant virus strains. This drug is effective against both HSV-1 and HSV-2 and is taken orally once daily.
Key data from the PRIOH-1 Phase 3 clinical trial (101 immunocompromised patients):
| Evaluation Index | Pritelivir Group | Conventional Treatment Group |
| :--- | :--- | :--- |
| **Complete healing of all lesions by 28 days** | **63%** | 34% |
| **Complete healing of all lesions by 42 days** | **82%** | 42% |
| **Discontinuation due to side effects** | **2%** | 20% |
| **Overall hospitalization rate** | **29.4%** | 76% |
The wound healing rate in the Pritelivir group was 28.4 percentage points higher than the conventional treatment group (P=0.0047), which is statistically and clinically significant. Its biggest clinical advantage is that it can be taken orally at home, avoiding the need for hospitalization and IV drips (such as foscarnet), which is crucial for patients with already weakened immune systems.
## Other New Drugs and Research Directions
In addition to Pritelivir, other helicase-primase inhibitors are also being developed. Adibelivir (IM-250) has shown potential to prevent reactivation of dormant viruses in preclinical research and has demonstrated synergistic effects when used in combination with acyclovir; it is currently in Phase 2. ABI-5366, a long-acting helicase-primase inhibitor, is expected to be taken once a month. In preliminary trials, it significantly reduced asymptomatic HSV-2 virus shedding.
In the field of gene editing, the Fred Hutch Cancer Center has used CRISPR-like techniques in mouse models to clear over 90% of inactive HSV-1 and also reduce viral shedding. However, this is still an animal experiment, primarily targeting HSV-1, and approximately 10% of mice in the high-dose group showed signs of liver damage. As of October 2026, Fred Hutch has not announced the start of human clinical trials for genital herpes or oral herpes.
## Vaccine Status: Still Challenging
Herpes vaccine research has yet to yield any breakthroughs. GSK's preventive vaccine was halted after Phase 2; Moderna's therapeutic vaccine, mRNA-1608, has completed Phase 1/2 trials and published preliminary safety and immune response data, but it has not yet been proven to effectively reduce disease outbreaks or transmission. A 2026 review article from the NIH stated that for an effective herpes vaccine, neutralizing antibodies alone are not sufficient, but rather both multifunctional antibodies and tissue-resident T cell immunity are required, as the herpes virus has a powerful immune evasion mechanism.
## Conclusion
A complete cure for herpes is still not possible in 2026. Pritlivir's approval is primarily for immunocompromised patients who are not responding to conventional medications, and it only controls symptoms, not eliminates dormant virus. Research into gene editing and new generation vaccines offers hope for future changes, but many years of safety and effectiveness validation are still needed before human application. If you suspect you have herpes, or would like to learn about treatment options, please consult a physician, and be wary of any unapproved product or treatment method claiming a "permanent cure."